A medical procedure is referred to as non- invasive when there is slight incision in body in diagnosis. There are various non- invasive diagnostics methods which range from simple observation to specialized surgery.
Europe Non-Invasive Cancer Diagnostics Market is worth USD xx million in 2018 and estimated to grow at a CAGR of xx.xx%, to reach USD xx million by 2023. The Europe Non-Invasive Cancer Diagnostics market is developing at an exceptionally quick pace.
The significant drivers are increasing incidence of cancer due aging, and increasing awareness about early cancer diagnosis. Advancements in cancer detection techniques is also expected to drive the market over the forecast period. However, high cost of treatment is a major restraint limiting this industry.
The Europe Non-Invasive Cancer Diagnostics market is segmented on the basis of therapeutics, techniques, and region. Based on therapeutics the market is segmented into Blood cancer, Breast Cancer, Lung Cancer, Solid tumors and others. Breast cancer had the largest market share. Based on techniques the market is segmented into Immunochemistry, Clinical Chemistry, Molecular Diagnostics, and Others.
By geography Non-Invasive Cancer Diagnostics market is classified into UK, Spain, Germany, France, Italy and others. Europe is assumed as developed market and is anticipated to witness significant growth in the forecast period.
Precision Therapeutics, Laboratory Corporation of America Holdings (LabCorp), BIOVIEW Inc., Affymetrix Inc., AVIVA Biosciences Corporation, A&G Pharmaceutical, Quest Diagnostics
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Techniques
5.1.1 Introduction
5.1.2 Clinical Chemistry
5.1.3 Immunochemistry/Immunoassay
5.1.4 Molecular Diagnostics
5.1.5 Other Clinical Instruments
5.1.6 Y-o-Y Growth Analysis, By Techniques
5.1.7 Market Attractiveness Analysis, By Techniques
5.1.8 Market Share Analysis, By Techniques
5.2 Type
5.2.1 Introduction
5.2.2 Breast Cancer
5.2.3 Blood cancer
5.2.4 Lung Cancer
5.2.5 Solid tumors
5.2.6 Others
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Techniques
6.1.3.3 By Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Techniques
6.1.4.3 By Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Techniques
6.1.5.3 By Type
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 AVIVA Biosciences Corporation
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Affymetrix Inc.
8.3 A&G Pharmaceutical
8.4 BIOVIEW Inc.
8.5 Digene Corporation
8.6 Gen-Probe Incorporated
8.7 Laboratory Corporation of America Holdings (LabCorp)
8.8 Precision Therapeutics
8.9 Quest Diagnostics Incorporated
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
